As of May 26
| -0.53 / -0.12%|
The 22 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 448.50, with a high estimate of 530.00 and a low estimate of 350.00. The median estimate represents a -1.47% decrease from the last price of 455.17.
The current consensus among 27 polled investment analysts is to Hold stock in Regeneron Pharmaceuticals. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.